Yatsen Holding Ltd (YSG) Q4 2025 Earnings Call Transcript

Why It Matters

The turnaround demonstrates Yatsen’s ability to boost profitability amid a sluggish Chinese beauty market, positioning its skincare and revitalized makeup brands as growth engines for 2025.

Key Takeaways

• Q4 revenue up 7.1% despite market slowdown
• Gross margin improved to 77.8% year‑over‑year
• Skincare share reached record 41.1% of sales
• Color cosmetics grew 16.4% in Q4
• Non‑GAAP profit margin turned positive at 9.3%

Pulse Analysis

China’s beauty sector faced a modest contraction in 2024, with overall retail sales of consumer goods rising only 3.5% and beauty sales slipping 1.1% year‑over‑year. Against this backdrop, Yatsen Holding managed to grow fourth‑quarter revenue by 7.1%, largely thanks to a robust rebound in its color‑cosmetics portfolio, highlighted by Perfect Diary’s 16.4% sales jump. The company’s gross margin expansion to 77.8% reflects a deliberate shift toward higher‑margin SKUs and a more disciplined cost structure, delivering a net loss margin reduction from 46% to 33% and a non‑GAAP net‑income margin of 9.3%.

Strategically, Yatsen has rebalanced its mix to prioritize premium skincare brands—Galenic, DR. WU, and Eve Lom—now contributing over 40% of total revenue and achieving record‑high market penetration. Heavy investment in R&D, representing 3.2% of full‑year revenue, underpins new product launches such as Galenic’s vitamin‑A serum and micro‑mask series, while Perfect Diary’s award‑winning lipsticks have expanded both online (Douyin) and offline distribution channels. These initiatives have not only driven top‑line growth but also enhanced operational efficiency, cutting operating expenses to 111.8% of revenue, down from 124% a year earlier.

Looking ahead, Yatsen projects first‑quarter 2025 revenue between RMB 788.8 million and RMB 866.2 million, implying 2%‑12% year‑over‑year growth. The firm’s focus on scaling high‑margin skincare while sustaining makeup momentum positions it to capture incremental market share as Chinese consumers become more value‑conscious. Investors should monitor the company’s ability to maintain margin expansion, manage goodwill impairments, and translate its R&D pipeline into repeatable sales, all of which will be critical to sustaining the profitability trend and delivering long‑term shareholder value.